Safety and Tolerability in Healthy Volunteers Clinical Trial
Official title:
A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.
This is a prospective, 8-day, randomized, double-blind, placebo-controlled, sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single escalating oral doses of NW-3509A in healthy male volunteers. Six independent cohorts of 12 volunteers each will participate in this study, with the first 9 volunteers in each cohort to qualify being randomized to receive study medication and the remaining 3 to be used as backups/ alternates. In each cohort, 6 subjects will be randomly assigned to receive NW-3509A and 3 subjects will receive placebo.
Doses from 1 to 30 mg were tested ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03672604 -
A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04535752 -
A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)
|
Phase 1 | |
| Completed |
NCT04783545 -
Phase I Study of VLX-1005 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04034784 -
Discrete(TM) Safety Clinical Trial GLAD-01
|
N/A | |
| Terminated |
NCT03010046 -
Single Dose Study of ANX005 in Healthy Volunteers
|
Phase 1 |